Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Soh, Junichi ^a,c   Okumura, Naoki ^a   Lockwood, William W ^d   Yamamoto, Hiromasa ^c   Shigematsu, Hisayuki ^c   Zhang, Wei ^a   Chari, Raj ^d   Shames, David S ^a,h   Tang, Ximing ^e   MacAulay, Calum ^d   Varella Garcia, Marileila ^f   Vooder, Tõnu ^g   Wistuba, Ignacio I ^e   Lam, Stephen ^d   Brekken, Rolf ^a   Toyooka, Shinichi ^c   Minna, John D ^a,b   Lam, Wan L ^d   Gazdar, Adi F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d British Columbia Cancer Centre   (Canada)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g TARTU UNIVERSITY HOSPITAL   (Estonia)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN;

ALLELE; ALLELIC IMBALANCE; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE NUMBER; GENETIC TRANSCRIPTION; HOMOZYGOSITY; HUMAN; HUMAN CELL; LUNG CANCER; MUTATIONAL ANALYSIS; ONCOGENE; PANCREAS CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; QUANTITATIVE STUDY; TUMOR XENOGRAFT; UNIPARENTAL DISOMY; WILD TYPE; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; MOLECULAR CLONING; MORTALITY; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLASMID; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR CELL LINE;

ALLELES; CELL LINE, TUMOR; CLONING, MOLECULAR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROZYGOTE; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASMS; ONCOGENES; PHENOTYPE; PLASMIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 70449433271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007464     Document Type: Article

References (45)

1. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
2. Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome aberrations in solid tumors. Nat Genet 34: 369-376.
3. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, et al. (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353-1362.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
6. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, et al. (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 4: e4576.
7. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
8. Engel E (1980) A new genetic concept: uniparental disomy and its potential effect, isodisomy. Am J Med Genet 6: 137-143.
9. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, et al. (2008) Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/ 2-associated ovarian carcinomas. Clin Cancer Res 14: 7645-7651.
10. Gupta M, Raghavan M, Gale RE, Chelala C, Allen C, et al. (2008) Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47: 729-739.
11. Melcher R, Al-Taie O, Kudlich T, Hartmann E, Maisch S, et al. (2007) SNP-Array genotyping and spectral karyotyping reveal uniparental disomy as early mutational event in MSS- and MSI-colorectal cancer cell lines. Cytogenet Genome Res 118: 214-221.
12. Tuna M, Knuutila S, Mills GB (2009) Uniparental disomy in cancer. Trends Mol Med 15: 120-128.
13. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, et al. (2005) Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65: 9152-9154.
14. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
15. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, et al. (2007) Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126.
16. Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, et al. (2007) Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis 28: 38-48.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
18. Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12: 104-107.
19. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
20. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, et al. (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62: 6451-6455.
21. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, et al. (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68: 9375-9383.
22. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, et al. (2008) PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. Cancer Res 68: 6913-6921.
23. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
24. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
25. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
26. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, et al. (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18: 752-760.
27. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
28. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, et al. (2006) Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116-2128.
29. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
30. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, et al. (2006) Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 12: 4043-4054.
31. Herrmann BG, Frischauf AM (1987) Isolation of genomic DNA. Methods Enzymol 152: 180-183.
32. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, et al. (2006) Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12: 43-48.
33. Soh J, Toyooka S, Ichihara S, Asano H, Kobayashi N, et al. (2008) Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 3: 340-347.
34. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
35. Chari R, Lockwood WW, Coe BP, Chu A, Macey D, et al. (2006) SIGMA: a system for integrative genomic microarray analysis of cancer genomes. BMC Genomics 7: 324.
36. Bengtsson H, Irizarry R, Carvalho B, Speed TP (2008) Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics 24: 759-767.
37. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
38. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T (2006) PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 1: 629-634.
39. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
40. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, et al. (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37: 1315-1316.
41. LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, et al. (2005) Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol 1: e65.
42. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500.
43. Uchiyama M, Usami N, Kondo M, Mori S, Ito M, et al. (2003) Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. Int J Cancer 107: 962-969.
44. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29: 25-33.
45. Gazdar AF, Minna JD (2008) Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops. Cancer Prevention Research 1: 5.